Xeltis develops world’s first bioabsorbable heart valve
Xeltis has successfully completed its second feasibility trial for its bioabsorbable cardiovascular device technology and displays positive results in patients a year after surgery
Xeltis is a medical device company developing the world’ first bioabsorbable cardiac valves and vessels designed to allow Endogenous Tissue Restoration (ETR).
The Xeltis products are made of bioabsorbable polymers structured as a porous matrix that is designed to work as valve or other cardiovascular component once implanted and to allow ETR, as the body’s natural healing process pervades it with new functioning tissue.
As the natural cardiovascular part forms, the matrix is structured to be absorbed and to leave the patients with their own healthy tissue.
Laurent Grandidier, CEO at Xeltis, said: “The positive results of our second feasibility trial confirm the extraordinary potential of our bioabsorbable technology for a number of different cardiovascular applications.
“We are confident that bioabsorbable cardiovascular devices will be able to replace most commonly used implantable devices and that ETR will improve patient outcomes while reducing the economic burden for healthcare systems.“
In the second trial study, young children born with only one functioning heart ventricle and requiring a Glenn procedure were implanted with a Xeltis cardiovascular patch as part of their operation.
Results showed that all patients presented no patch-related post-operative complications and no functional impairment requiring intervention a year after surgery.
The study was led by Professor Leo Bockeria, a cardiac surgeon, at the Bakoulev Center for Cardiovascular Surgery in Moscow, Russia.
Bockeria said: “The results of this study are beginning to build clinical evidence about the feasibility of bioabsorbable cardiovascular devices as new therapeutic options in cardiovascular surgery.
“A year after surgery, all clinical parameters are positive and provide hope that ETR may offer a more definitive solution to a number of cardiac conditions.”